Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines.
Since 2002 Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders.
Incyte’s unique expertise in medicinal chemistry and biology have enabled us to create a diversified pipeline of clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing portfolio of medicines across Oncology and Inflammation & Autoimmunity.
Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For more information, visit Incyte.com and follow @Incyte.
Hemosure is a worldwide recognized trade name in immunological fecal occult blood testing, also known as iFOB or FIT testing. Colorectal Cancer (CRC), when discovered in the early stages, is the most preventable and curable of all cancers. Routine CRC screening is extremely important, which is why Hemosure is dedicated and focused on educating physicians and patients on this subject. We, at Hemosure, are proud to manufacture the fastest growing Fecal Immunochemical Test (FIT) and have established its place as an industry leader.
Hemosure prides itself in being simple to use both in the collection process as well as the implementation of the test. Patients are provided everything they will need for the collection process as well as easy to understand instructions that Hemosure makes available in hard copy, as well as online in multiple languages along with detailed instructions.Hemosure, providing industry leading technology.
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.
In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. In 2021, JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 administered with bamlanivimab, was granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116 (deuremidevir hydrobromide), a novel oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company’s continuous efforts towards innovation for disease control and prevention of the global pandemic.
Junshi Biosciences has about 3,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc).
For more information, please visit: https://www.junshipharma.com/en
